An evaluation of torsemide in patients with heart failure and renal disease

References

• Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics—2021 update: a report from the American heart association. Circulation. 2021;143(8):e254–e743.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States a policy statement from the American heart association. Circ Hear Fail. 2013;6(3):606–619.
   PubMed Web of Science ®Google Scholar
• Metra M, Teerlink JR. Heart failure. Lancet. 2017;390(10106):1981–1995.
   PubMed Web of Science ®Google Scholar
• Murphy SP, Ibrahim NE, Januzzi JL. Heart failure with reduced ejection fraction: a review. J Am Med Assoc. 2020;324(5):488–504.
   PubMed Web of Science ®Google Scholar
• James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and Injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1789–1858.
   PubMed Web of Science ®Google Scholar
• Vergaro G, Ghionzoli N, Innocenti L, et al. Noncardiac versus cardiac mortality in heart failure with preserved, midrange, and reduced ejection fraction. J Am Heart Assoc. 2019;8(20). DOI:https://doi.org/10.1161/JAHA.119.013441.
   Google Scholar
• Ahmed A, Campbell RC. Epidemiology of chronic kidney disease in heart failure. Heart Fail Clin. 2008;4(4):387–399.
   PubMedGoogle Scholar
• Hebert K, Dias A, Delgado MC, et al. Epidemiology and survival of the five stages of chronic kidney disease in a systolic heart failure population. Eur J Heart Fail. 2010;12(8):861–865.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol [Internet]. 2013;62:e147–e239. Available from.;(16):.
   PubMed Web of Science ®Google Scholar
• Khan MS, Greene SJ, Hellkamp AS, et al. Diuretic changes, healthcare resource utilization, and clinical outcomes for heart failure with reduced ejection fraction: from the CHAMP-HF registry. Circ Hear Fail. 2021;14(11):In press. doi:https://doi.org/10.1161/CIRCHEARTFAILURE.121.008351.
   Google Scholar
• Buggey J, Mentz RJ, Pitt B, et al. A reappraisal of loop diuretic choice in heart failure patients. Am Heart J Internet]. 2015;169:323–333. Available from.;(3):.
   PubMed Web of Science ®Google Scholar
• Dinicolantonio JJ. Should torsemide be the loop diuretic of choice in systolic heart failure? Future Cardiol. 2012;8(5):707–728.
   PubMedGoogle Scholar
• Knauf H, Mutschler E. Clinical pharmacokinetics and pharmacodynamics of torasemide. Clin Pharmacokinet. 1998;34(1):1–24.
   PubMed Web of Science ®Google Scholar
• Wargo KA, Banta WM. A comprehensive review of the loop diuretics: should furosemide be first line? Ann Pharmacother. 2009;43(11):1836–1847.
   PubMed Web of Science ®Google Scholar
• Vasko MR, Cartwright DB, Knochel JP, et al. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med. 1985;102(3):314–318.
   PubMed Web of Science ®Google Scholar
• Brater DC, Day B, Burdette A, et al. Bumetanide and furosemide in heart failure. Kidney Int. 1984;26(2):183–189.
   PubMed Web of Science ®Google Scholar
• Bleske BE, Welage LS, Kramer WG, et al. Pharmacokinetics of torsemide in patients with decompensated and compensated congestive heart failure. J Clin Pharmacol. 1998;38(8):708–714.
   PubMed Web of Science ®Google Scholar
• Gehr TWB, Rudy DW, Matzke GR, et al. The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin Pharmacol Ther. 1994;56(1):31–38.
   PubMed Web of Science ®Google Scholar
• Rudy DW, Gehr TWB, Matzke GR, et al. The pharmacodynamics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin Pharmacol Ther. 1994;56:39–47.
   PubMed Web of Science ®Google Scholar
• Shah S, Pitt B, Brater DC, et al. Sodium and fluid excretion with torsemide in healthy subjects is limited by the short duration of diuretic action. J Am Heart Assoc. 2017;6(10):1–8.
   Web of Science ®Google Scholar
• Vormfelde SV, Brockmöller J. The genetics of loop diuretic effects. Pharmacogenomics J. 2012;12:45–53.
   PubMed Web of Science ®Google Scholar
• Lambe R, Kennedy O, Kenny M, et al. Study of the tolerance and diuretic properties of torasemide following oral or intravenous administration to healthy volunteers. Eur J Clin Pharmacol. 1986;31(S1):9–14.
   PubMed Web of Science ®Google Scholar
• Veeraveedu PT, Watanabe K, Ma M, et al. Comparative effects of torasemide and furosemide in rats with heart failure. Biochem Pharmacol. 2008;75(3):649–659.
   PubMed Web of Science ®Google Scholar
• Broekhuysen J, Deger F, Douchamps J, et al. Torasemide, a new potent diuretic - Double-blind comparison with furosemide. Eur J Clin Pharmacol. 1986;31(S1):29–34.
   PubMed Web of Science ®Google Scholar
• Goebel KM. Six-week study of torsemide in patients with congestive heart failure. Clin Ther. Internet]. 1993;15(6):1051–1059. Available from http://europepmc.org/abstract/MED/8111802
   PubMed Web of Science ®Google Scholar
• Bayliss J, Norell M, Canepa-Anson R, et al. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57(1):17–22.
   PubMedGoogle Scholar
• Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82(5):1724–1729.
   PubMed Web of Science ®Google Scholar
• Uchida T, Yamanaga K, Nishikawa M, et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol. 1991;205(2):145–150.
   PubMed Web of Science ®Google Scholar
• Goodfriend TL, Ball DL, Oelkers W VB. Torsemide Inhibits Aldosterone Secretion In Vitro. Life Sci. 1998;63(3):45–50.
   PubMed Web of Science ®Google Scholar
• McCurley JM, Hanlon SU, Wei SK, et al. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol Internet]. 2004;44:1301–1307. Available from.;(6):.
   PubMed Web of Science ®Google Scholar
• Veeraveedu PT, Watanabe K, Ma M, et al. Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy. Eur J Pharmacol. 2008;581(1–2):121–131.
   PubMed Web of Science ®Google Scholar
• Tsutamoto T, Sakai H, Wada A, et al. Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure [3]. J Am Coll Cardiol Internet]. 2004;44:2252–2253. Available from.;(11):.
   PubMed Web of Science ®Google Scholar
• Yamato M, Sasaki T, Honda K, et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J. 2003;67(5):384–390.
   PubMed Web of Science ®Google Scholar
• Gravez B, Tarjus A, Jimenez-Canino R, et al. The diuretic torasemide does not prevent aldosterone-mediated mineralocorticoid receptor activation in cardiomyocytes. PLoS One. 2013;8(9):e73737.
   PubMed Web of Science ®Google Scholar
• López B, Querejeta R, González A, et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004;43(11):2028–2035.
   PubMed Web of Science ®Google Scholar
• López B, González A, Beaumont J, et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol. 2007;50(9):859–867.
   PubMed Web of Science ®Google Scholar
• Kasama S, Toyama T, Hatori T, et al. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart. 2006;92(10):1434–1440.
   PubMed Web of Science ®Google Scholar
• The Torafic Investigators Group. Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study. Clin Ther. 2011;33(9):1204–1213.e3.
   PubMed Web of Science ®Google Scholar
• Trippel TD, Van Linthout S, Westermann D, et al. Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial). Eur J Heart Fail. 2018;20(3):460–470.
   PubMed Web of Science ®Google Scholar
• Murray MD, Deer MM, Ferguson JA, et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111(7):513–520.
   PubMed Web of Science ®Google Scholar
• Müller K, Gamba G, Jaquet F, et al. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV - Efficacy and quality of life. Eur J Heart Fail. 2003;5(6):793–801.
   PubMed Web of Science ®Google Scholar
• Cosín J, Díez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4(4):507–513.
   PubMed Web of Science ®Google Scholar
• Balsam P, Ozierański K, Marchel M, et al. Comparative effectiveness of torasemide versus furosemide in symptomatic therapy in heart failure patients: preliminary results from the randomized tornado trial. Cardiol J. 2019;26(6):661–668.
   PubMed Web of Science ®Google Scholar
• Vasavada N, Saha C, Agarwal R. A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. Kidney Int. 2003;64(2):632–640.
   PubMed Web of Science ®Google Scholar
• Hein OV, Staegemann M, Wagner D, et al. Torsemide versus furosemide after continuous renal replacement therapy due to acute renal failure in cardiac surgery patients. Ren Fail. 2005;27(4):385–392.
   PubMed Web of Science ®Google Scholar
• Bikdeli B, Strait KM, Dharmarajan K, et al. Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives? J Am Coll Cardiol Internet]. 2013;61:1549–1550. Available from.;(14):.
   PubMed Web of Science ®Google Scholar
• Shah P, Patel H, Mithawala P, et al. Torsemide versus furosemide in heart failure patients: a meta-analysis of randomized controlled trials. Eur J Intern Med. 2018;57:e38–e40.
   PubMed Web of Science ®Google Scholar
• Kido K, Shimizu M, Hashiguchi M. Comparing torsemide versus furosemide in patients with heart failure: a meta-analysis.J Am Pharm Assoc Internet]. 2019;59(3):432–438.
   Google Scholar
• Miles JA, Hanumanthu BK, Patel K, et al. Torsemide versus furosemide and intermediate-term outcomes in patients with heart failure: an updated meta-analysis. J Cardiovasc Med. 2019;20(6):379–388.
   Google Scholar
• Abraham B, Megaly M, Sous M, et al. Meta-analysis comparing torsemide versus furosemide in patients with heart failure. Am J Cardiol [Internet]. 2020;125:92–99. [Internet].;(1):.
   PubMed Web of Science ®Google Scholar
• Sherif NA, Morra ME, Van TL, et al. Torasemide versus furosemide in treatment of heart failure: a systematic review and meta-analysis of randomized controlled trials. J Eval Clin Pract. 2020;26(3):842–851.
   PubMed Web of Science ®Google Scholar
• Kido K, Shimizu M, Hashiguchi M. Comparing torsemide versus furosemide in patients with heart failure: a meta-analysis. J Am Pharm Assoc. 2019;59(3):432–438.
   Google Scholar
• Greene SJ, Velazquez EJ, Anstrom KJ, et al. Pragmatic design of randomized clinical trials for heart failure: rationale and design of the TRANSFORM-HF trial. JACC Hear Fail. 2021;9(5):325–335.
   PubMed Web of Science ®Google Scholar